BSEInsider Trading / SASTPledge4 Sept 2026
Asston Pharmaceuticals Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Asston Pharmaceuticals Ltd received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali, indicating a change in promoter holding from 7.26% to 9.03% through open market purchases.
BSEInsider Trading / SASTRegulatory2 Sept 2026
Asston Pharmaceuticals Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Asston Pharmaceuticals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali, indicating a significant acquisition of shares in the company.
BSEInsider Trading / SASTRelated Party1 Sept 2026
Asston Pharmaceuticals Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Asston Pharmaceuticals Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Prakruti R Pali, which will be submitted to the BSE.
BSEInsider Trading / SASTRelated Party31 Aug 2026
Asston Pharmaceuticals Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali
Asston Pharmaceuticals Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prakruti R Pali.
BSEBoard MeetingMgmt Change27 Aug 2026
Asston Pharmaceuticals Ltd
Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. Appointment of M/s ....
Asston Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/09/2026 to consider and approve various matters, including the appointment of a new statutory auditor, increase in remuneration of directors, and the date and draft notice of the 7th Annual General Meeting.
BSEAGM/EGM3 Aug 2026
Asston Pharmaceuticals Ltd
Voting Result and Scrutinizer report for EGM held on 31st July, 2026 through VC-OAVM
Asston Pharmaceuticals Ltd has announced the voting results and scrutinizer's report for its Extraordinary General Meeting (EGM) held on July 31, 2026, through video conferencing. The meeting was attended by 3 promoters and 0 public shareholders, and 1 resolution was passed, which was to issue equity shares on a preferential basis.
BSEAGM/EGM31 Jul 2026
Asston Pharmaceuticals Ltd
Outcome and Proceedings of the 2nd Extraordinary General Meeting for F.Y. 2026-27, scheduled to be held on 31st July, 2026, at 12:30 P.M. through Video Conferencing and Other Audio-Visual Means.
Asston Pharmaceuticals Ltd held its 2nd Extraordinary General Meeting on 31st July, 2026, via video conferencing, to discuss and pass resolutions. The meeting was conducted in accordance with the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The requisite quorum was present, and the resolutions were taken as read with the consent of the members. The company provided its members with the facility to cast their vote electronically through the NSDL system before the meeting and also made available the remote e-voting facility from 28th July, 2026, to 30th July, 2026.